Abstract: A method for feeding poultry is provided and includes the steps obtaining a feed supplement composition including an aqueous ethanol extract isolated from leafy parts of Amaranthus hybridus by using a mixture of water and ethanol as an extractive agent, in which mixture an amount of ethanol is within a range of 0.1-85 vol %, admixing the composition into a basal poultry feed or drinking water in a predetermined amount of at least 0.003 g/kg, and administering the resulting mixture to poultry in accordance with predetermined dosage regimen. The composition may be also utilized as a phytogenic feed supplement for poultry, depending on dosage regime, administration duration, and on age and category of poultry stock.

Abstract: Compositions and formulations comprising polymeric myrcene. More particularly, the invention relates to compositions comprising an isolated fraction of polymeric myrcene in a hydrophobic carrier and formulations which maintain the biological activity of the active polymer.

Abstract: Described herein are beverages that can enhance sexual performance in both men and women. For example, the beverages are useful in promoting endurance and stamina and in increasing sexual desire as well as blood flow to the genital region. Components of the beverages are also associated with a reduced risk of cardiovascular disease in subjects who consume the beverages. The beverages are composed of pomegranate juice, ginseng, maca root, and L-arginine or a pharmaceutically acceptable salt thereof. The beverages may additionally include B complex vitamins including folic acid, as well as Tongkat Ali and/or damiana leaf. Vitamins, minerals, other nutrients, and other natural products can also be added to the beverages to provide additional health benefits.

Abstract: The invention is directed to compositions for the prophylaxis, treatment and recovery of overtraining syndrome. Compositions comprising a combination of parts of plants or plant extracts belonging to Crassulaceae, Araliaceae and Schisandraceae for the prophylaxis and treatment of overtraining syndrome. In a preferred embodiment the composition further comprises parts of plants or plant extracts of Asteraceae and or pantothenic acid or salts thereof.

Abstract: The present disclosure is drawn to a topical skin care formulation comprising Calendula and Rooibos. Other ingredients can optionally be included, such as DMAE.

Abstract: Discloses is a single herb extract for the treatment of PCOS (Poly Cystic Ovarian Syndrome) when given in oral dosage form as capsules of 500 mg, twice a day for period of time ranging from 30-90 days, The extract is obtained from fenugreek seeds using a specific method of extraction and comprises five furostanolicsaponins present in synergistic ratios as in Table 1 and having analytical profile as in FIG. 1.

Abstract: The present invention relates to a lactic acid fermented product of cassia seeds. The fermented product of the present invention uses cassia seeds, which have long been used and have proven their safety without causing side effects. Due to this advantage, the lactic acid fermented product of the present invention is effective in increasing the number, water content, and/or weight of feces. The effects of the lactic acid fermented product according to the present invention are comparable to those of sennoside, which is a therapeutic agent for stimulant constipation and whose use in health functional foods is forbidden because of its side effects, and Dulcolax-S, which is currently commercially available and includes bisacodyl and sodium docusate as active ingredients. Therefore, the lactic acid fermented product of the present invention can be utilized in pharmaceutical compositions for treating or preventing constipation or health functional foods for ameliorating or preventing constipation.

Abstract: The Toona sinensis extract of the present invention is prepared using supercritical fluid technique, wherein the method includes steps of: (a) drying the leaves of T. sinensis; (b) pulverizing the leaves as particles; and (c) extracting the particles with supercritical carbon dioxide to obtain the T. sinensis extract. This supercritical T. sinensis extract not only can decrease blood sugar level, but also promotes lipid degradation, inhibits the formation of huge lipid droplet and improves the metabolic symptoms. Accordingly, the T. sinensis extract further is able to be prepared as food supplement and pharmaceuticals.

Abstract: A naturopathic wound treatment product comprising a mixture of 0.55-0.75% by weight vitamin E oil, 40-60% by weight extra virgin coconut oil, 40-60% by weight aloe, and 0.1-0.3% by weight beta glucan, 3.5-4.5% by weight colloidal silver. All weights are based on a total weight of the product. The vitamin E oil, extra virgin coconut oil, aloe, beta glucan, and colloidal silver are combined to form a single mixture.

Abstract: The present invention provides a method for preventing, alleviating or treating a liver disease, comprising administering a composition comprising a Triticum aestivum Lamarck leaf extract or a fraction thereof to a subject in need thereof. Therefore, the method for preventing, alleviating or treating a liver disease of the present invention can improve the morphological change of liver tissue due to liver injury, inhibit apoptosis of hepatocytes, increase the synthesis of antioxidant enzymes such as glutathione (GSH) and superoxide dismutase (SOD) which can reduce oxidative stress in liver tissue, and reduce the levels of glutamic oxaloacetic transaminase (GOT) and glutamic pyruvic transaminase (GPT) which are known to change sensitively in liver diseases.

Abstract: Methods for treating pancreatic cancer via administration of small anti-inflammatory peptides. The peptides may be administered in conjunction with another therapeutic agent or therapeutic regimen.

Abstract: Methods for treating subjects suffering from chronic kidney disease-mineral and bone disorder or other disorders resulting in primary or secondary hyperparathyroidism are described. The methods are effective in reducing serum parathyroid hormone (PTH) levels and calcium levels in patients who undergo hemodialysis. The methods described herein are also effective in slowing the progression of kidney disease and preserving kidney function. Compositions used in the described methods are also provided and comprise calcimimetics which function as agonists of the calcium sensing receptor (CaSR).

Abstract: The present invention generally relates to compositions and methods for treatment of subjects in need of muscle growth, muscle repair, improved muscular and neuromuscular control, and treatments for neuromuscular and neurological disorders, including brain disorders. In some cases, the composition may include nitric oxide and/or peptides such as thyrotropin-releasing hormone (TRH) and/or GnRH (gonadotropin-releasing hormone). The nitric oxide and/or peptides may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other structures containing nitric oxide and/or peptide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., onto a location where muscle growth, muscle repair, or improved muscular and neuromuscular control is desired, or on another suitable portion of the skin.

Abstract: The present invention relates to pharmaceutical and food compositions for inducing satiation and prolonging satiety in subjects in need thereof. In particular, the present invention relates to a method of inducing satiation in a subject in need thereof comprising administering to the subject an effective amount of a ClpB protein or an effective amount of a bacterium that expresses the ClpB protein.

Abstract: This invention provides a method of inducing a lacrimal acinar cell in a tissue to degrade a secretory vesicle and its content protein or proteins from the trans-Golgi network (TGN) by contacting the cells with an effective amount of an agent that induces autophagy. Also provided is a method for treating a mammal suffering from defective trans-Golgi network-secretory vesicle (TGN-SV) sorting by administering to the mammal an effective amount of an agent that induces autophagy in the tissue having the defective TGN-SV.

Abstract: Described herein are systems and methods for attracting and trapping cancer cells at a specific site where focal radiation and/or surgical resection and/or chemotherapeutics can eliminate them.

Abstract: The invention provides methods for treating tissue damage associated with impaired blood flow using ApoD, or an active variant thereof, or an agent that increases the expression of ApoD. The invention also encompasses active variants of ApoD for use in the methods.

Abstract: Provided are methods and compositions for protecting treating ischemic events in the retina. The methods include administering a MANF family protein (e.g., MANF, CDNF, or fragments thereof) to a subject and performing another treatment to resolve the blockage underlying the ischemic event. The methods also include administering a MANF family protein to extend the therapeutic window for treatment of a retinal artery occlusion.

Abstract: A method of diagnosing a subject's percentage of probability of retrieval of oocytes based on an age of the subject by selecting the percentage that matches the subject's AMR level in accord with plotted curves for retrieval of ?1, ?2, ?3, ?4 and ?5 oocytes and administering AMR to the subject, as warranted, to increase the AMR level to attain a desired percentage of probability of retrieval of oocytes based upon the age of the subject and in accord with a matching percentage for the increased AMR level from plotted curves for retrieval of ?1, ?2, ?3, ?4 and ?5 oocytes.

Abstract: The present invention relates, e.g., to a method for inducing arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis, and/or for inducing mitosis or proliferation of a smooth muscle cell, a skeletal muscle cell, or a cardiomyocyte, comprising administering to a cell or tissue in need thereof a dose of a polynucleotide that encodes a vascular endothelial growth factor (VEGF), or that encodes a polypeptide comprising an active site of the VEGF. The coding sequence is operably linked to an expression control sequence; and the dose is sufficient to induce arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis, and/or to induce mitosis or proliferation of a smooth muscle cell, a skeletal muscle cell, or a cardiomyocyte. In preferred embodiments of the invention, the method is a method of tissue regeneration, particularly of cardiomyogenesis; and the polynucleotide (or a polypeptide encoded by such a polynucleotide) is administered into the myocardium.

Abstract: This invention relates to treatment of neuroinjury in a post-acute window or in a chronic period following neuroinjury.

Abstract: The present invention provides new protease resistant polypeptides, as well as compositions and methods for treating, ameliorating or preventing conditions related to joint damage, including acute joint injury and arthritis.

Abstract: The present invention relates to the GLP-1 receptor agonist liraglutide for use in medicine.

Abstract: The use of GLP-1 receptor agonists, such as glucagon-like peptide-1 (GLP-1) or exenatide, for the treatment of cancer is described. The GLP-1 receptor agonists are typically delivered using an implanted osmotic delivery device that provides for continuous delivery of the GLP-1 receptor agonist for at least one month. Additional beneficial agents, such as anticancer agents, can also be administered.

Abstract: The invention provides non-hormonal vitamin D conjugated to insulin peptides that result in the peptides having increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. The vitamin D targeting groups are coupled to the insulin peptides via the third carbon on the vitamin D backbone.

Abstract: This disclosure relates to compositions comprising a fibrin polymer produced by mixing platelet lysates with a minimal essential medium and thrombin. Typically, an optimized concentration of a calcium salt is utilized. In certain embodiments, the disclosure contemplates compositions comprising a fibrin polymer made by processes disclosed herein that contains cells, endothelial cells, stem cells, adipose tissue derived stem cell (ASC), and/or human mesenchymal stem cells (MSCs). In certain embodiments, the disclosure contemplates uses of composition disclosed herein containing cells, or cells replicated in compositions reported herein, to improve vascularizing, repairing, and healing of a tissue due to an ischemic condition or injury.

Abstract: The invention relates to factor VIII compositions and their use.

Abstract: Disclosed is a delivery device for delivering a payload, including a biological, chemical or biochemical substance, to a subject. The delivery device has a nanoparticle loaded with the payload, and porous coating structure over the loaded nanoparticle to prevent the payload from escaping the delivery device, while also preserving the activity of the payload and increasing effective utilization of the payload. Also disclosed is a delivery device for delivering a payload, including a natural virus, recombinant virus, or engineered virus. Also disclosed is a delivery device that has a liposome loaded with the payload and a biocompatible surface coating over the loaded liposome. Also disclosed are methods of fabricating the delivery devices and methods of using the delivery devices in treating health conditions, such as cancer, or in diagnostic applications.

Abstract: The present invention includes compositions and methods for treating disease and disorders associated with pathological calcification or pathological ossification by modulating the level or activity of NPP1 or a mutant thereof, or a mutant NPP4 modified to exhibit ATP hydrolase activity similar to the hydrolase activity of NPP1.

Abstract: A method of treating circadian rhythm disorders includes identifying a subject with a circadian rhythm disorder or at least one symptom of a circadian rhythm disorder and administering an effective amount of a composition comprising a botulinum toxin and a pharmaceutically acceptable carrier to said subject thereby reducing at least one symptom of a circadian rhythm disorder.

Abstract: The invention relates to methods of treatment of medical conditions (e.g., diseases and injuries) in a mammal (e.g., a human), such as hypoxia/ischemia, burns, and viral infections (e.g., influenza, West Nile virus, and Dengue fever), in adults and in children (e.g., neonates) by administering a composition that includes an IAIP.

Abstract: Protein antigens are provided. The protein antigens typically include a peptide antigen conjugated or fused to a chaperone protein to form a “chaperone-antigen” that increases lymph node uptake; improves an immune response; or a combination thereof relative to the peptide antigen alone. The immune response can be, for example, increased antigen-specific proliferation, enhanced cytokine production, stimulation of differentiation and/or effector functions, promotion of survival, rescue from exhaustion and/or anergy of T cells, or a combination thereof. Chaperon-antigens can also be used to induce tolerance and increase immune suppressive responses. In the most preferred embodiments, the peptide antigen is fused to the chaperone protein to form a fusion protein. The “chaperone-antigen” can be combined with an adjuvant to form a vaccine and administered to a subject to modulate an immune response to the antigen.

Abstract: A genetically modified coccidian parasites wherein expression of phosphatidylthreonine synthase (PTS) is disrupted, a polynucleotide including a nucleotide sequence encoding a phosphatidylthreonine synthase (PTS) enzyme, which catalyzes the production of a lipid, phosphatidylthreonine (PtdThr). PtdThr is an exclusive, major and physiologically important lipid in selected coccidian parasites, which is required for a normal growth and virulence of coccidian parasites. Coccidian parasites, having the expression of PTS disrupted as described herein, are useful as vaccines. The phosphatidylthreonine synthase enzyme and the nucleotide encoding sequences thereof as well as the phosphatidylthreonine phospholipid can find use in diagnostic methods and diagnostic kits or in vaccine and drug development applications.

Abstract: Disclosed herein are mutant Plasmodium-species parasites that are genetically attenuated (GAP). They retain the ability to infect a host and invade host hepatocytes but subsequently their development is completely arrested within the liver stage of Plasmodium development and the parasites do not reach the blood stage of development. Vaccines and pharmaceutical compositions comprising genetically attenuated Plasmodium sporozoites as well as methods of using the same are likewise provided.

Abstract: The technology provided herein relates to novel malaria vaccines composed of different recombinant proteins, in particular recombinant fusion proteins comprising several different Plasmodium falciparum antigens from the pre-erythrocytic, the blood, and the sexual parasite main stages. The proteins may be used in a mixture vaccine formulation to elicit protective immune responses in humans. Nucleic acid molecules encoding said recombinant proteins, vectors and host cells containing the nucleic acids and methods for preparation and producing such proteins are also disclosed, as well as antibodies induced or generated by the use of said malaria vaccines and the use of such antibodies or recombinant derivatives for passive immunotherapy.

Abstract: Compounds disclosed herein are effective against Ralstonia pickettii for treating or preventing insulin resistance, obesity or type II diabetes of a subject, and include an antibiotic effective against Ralstonia pickettii, an immunogenic compound producing a protective immune response, or an antibody which specifically binds to Ralstonia pickettii or a fragment thereof. In vitro methods for diagnosis or prediction of insulin resistance, obesity or type II diabetes include determining the presence of Ralstonia pickettii or of an antibody which specifically binds to Ralstonia pickettii in a test sample. An antibody binding specifically to an antigen of Ralstonia pickettii, a Ralstonia pickettii cell, or a nucleic acid hybridizing under stringent conditions to a nucleic acid from Ralstonia pickettii is disclosed. A kit including said antibody, the nucleic acid, and optionally a Ralstonia pickettii bacteria or a nucleic acid or protein thereof, a further reagent or a conventional kit component, is also disclosed.

Abstract: Stage-specific Borrelia antigens for diagnosing, treating and/or preventing Lyme disease are provided. The antigens include chimeric Borrelia antigen constructs and mutant recombinant proteins comprising OspC and OspE epitopes, respectively. The antigens are used in multiprotein assays that differentiate early, middle and late stage infection, and/or in vaccine preparations.

Abstract: Methods of immunizing older adult subjects against Streptococcus pneumoniae infection are provided. Provided methods comprise immunization of naive adult subjects with a conjugated pneumococcal polysaccharide vaccine. Optionally, initial immunization may be followed by additional immunization doses comprising conjugated pneumococcal polysaccharide vaccine or unconjugated pneumococcal polysaccharide vaccine composition.

Abstract: Purified Chlamydia major outer membrane protein (MOMP) has been observed to induce protection against genital and respiratory challenge in mice. MOMP contains variable domains that are highly immunogenic and elicit cross-serovar neutralizing monoclonal and polyclonal antibodies and T cell responses in animal and human models. Examples herein provide a method for vaccinating a subject against Chlamydia using a composition that is a recombinant Neisseria porin that contains at least one antigenic variable domain of Chlamydia. The variable domains are inserted into the amino acid sequence of the Neisseria porin at a position encoding a surface-exposed loop of the Neisseria porin. The vaccine further contains an adjuvant that induces a Th1 response greater than a Th2 response.

Abstract: Provided is a virus like particle comprising one or more zika virus structural proteins, and a composition or vaccine comprising thereof, its use in the prevention or treatment of zika virus disease. The zika virus structural protein contains at least one amino acid alteration in the envelope protein.

Abstract: The disclosed method provides an alternative approach of preventative vaccination which consists primarily of extracting and purifying monocytes, naive T and B lymphocytes from a patient and educating said lymphocytes against a pathogen in vitro until a population of antigen-specific memory lymphocytes are created with a memory against an infectious agent. Said memory lymphocytes are administered to a subject in a solution which consist primarily of blood plasma derived from said subject. In embodiments, one will see a vaccine approach wherein said vaccine excludes the inoculation of attenuated or killed whole pathogens, where inoculation of said vaccine does not illicit an immune response upon inoculation, and where said vaccine excludes chemicals such as thimerosal, formaldehyde, and aluminum which is all shunned by anti-vaccinators.

Abstract: The present invention discloses and claims virus like particles (VLPs) that express and/or contains seasonal influenza virus proteins, avian influenza virus proteins and/or influenza virus proteins from viruses with pandemic potential. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising VLPs of the inventions. The invention also includes methods of making and administrating VLPs to vertebrates, including methods of inducing substantial immunity to either seasonal and avian influenza, or at least one symptom thereof.

Abstract: The present invention relates to equine influenza virus (EIV) isolates that when administered in vaccines to equine provide protection against currently emerging EIV strains in the U.S. The present invention also relates to inactivated EIV isolates. In addition, the present invention also relates to safe and efficacious vaccines that comprise the EIV isolates, as well as to corresponding subunit vaccines. The present invention further relates to methods of administering such safe and efficacious vaccines to equine.

Abstract: The disclosed method provides a direct method for creating immunological memory against HIV by educating a patient's naive T and B lymphocytes in vitro into HIV antigen-specific adaptive immune memory lymphocytes. Said memory lymphocytes which were created in vitro undergo process wherein memory B lymphocytes are genetically modified for broadly neutralizing antibodies, as well as repeatedly stimulated with HIV antigens. Memory T lymphocytes undergo gene editing for chemokine receptors used by HIV for infection. Said memory lymphocytes are administered to said patient with an immunological memory against HIV in a solution which does not contain chemicals that are opposed to anti-vaccine supporters.

Abstract: The present invention is directed to a polymeric carrier cargo complex, comprising as a cargo at least one nucleic acid molecule and as a preferably non-toxic and non-immunogenic polymeric carrier disulfide-crosslinked cationic components for use as an immunostimulating agent or as an adjuvant, wherein the polymeric carrier cargo complex is administered in combination with at least one second nucleic acid molecule, which encodes a protein or peptide. The inventive polymeric carrier cargo complex administered in combination with the second nucleic acid molecule allows for both efficient transfection of nucleic acids into cells in vivo and in vitro and/or for induction of an innate and/or adaptive immune response, preferably dependent on the nucleic acid to be transported as a cargo and on the second nucleic acid molecule.

Abstract: The present invention relates to a medium composition for production of botulinum toxin and, more particularly, to a medium composition for culture of Clostridium sp. capable of producing botulinum toxin. The medium composition of the present invention comprises a casein hydrolysate and at least one plant-derived peptone selected from the group consisting of a garden pea hydrolysate, a cotton seed hydrolysate and a wheat gluten hydrolysate. When the medium according to the present invention, which contains plant-derived peptones, casein hydrolysates and minerals, is used for culture of Clostridium botulinum, the growth rate of the bacterium in the medium is higher than that in each of the medium that is in current use and the medium comprising plant-derived peptones alone. In addition, when the medium of the present invention is used, a high concentration of botulinum toxin can be produced by culturing the bacterium in a safe manner.

Abstract: The present disclosure provides novel macrocyclic compounds which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.

Abstract: The present invention provides methods of treating disease by modulation of PSMA activity. Such modulations can lead to, for example, alterations in cancer tumor metabolism, oxygenation, vascularization, and metastasis. The present invention encompasses the recognition that PSMA, through its role in a complex signaling cascade, can affect cancer progression, angiogenesis, and neovascularization. The present invention provides, among other things, methods of treating cancer, including but not limited to cancer initiation, progression, metastasis, and vascularization by modulation of PSMA activity.

Abstract: The present invention provides compositions and methods of for improving the Health-Related Quality of Life of a subject suffering from rheumatoid arthritis, comprising administering to the subject an effective amount of sarilumab.

Abstract: A pharmaceutical product comprising (a) a conjugation product of TNF and a tumour- or tumour vasculature-targeting peptide comprising an NGR, DGR, isoDGR or RGD motif; and (b) a cell comprising a chimeric antigen receptor (CAR), wherein the CAR comprises an antigen-specific targeting domain which targets a tumour antigen.